RxDoctor Payments Data

Temidayo Olurin, MD

Ophthalmology · Wilmington, DENPI 1093710691

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.2% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 28.7% of the total. That places this record below the midpoint for ophthalmology clinicians in DE, where the typical reported total is $1,099.

$669in general payments, 2019–2025

Across 11 payments — averaging $60.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$192
  • Biotissue Holdings Inc.$122
  • Genentech USA, Inc.$114
  • Topcon Healthcare, Inc.$86
  • Mallinckrodt Hospital Products Inc.$65
  • Carl Zeiss Meditec AG$39
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$63094%
  • Gifts$396%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$669 in reported general payments places this provider in the 35th percentile of 49 ophthalmology providers in Delaware.

See all ophthalmology providers in Delaware

Medicare billing

Part B allowed, 2024
$113,136
Medicare patients
472
Services billed
970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost61$40,458
CombiganBrimonidine Tartrate/Timolol29$19,198
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol71$17,522
Latanoprost470$6,420
SimbrinzaBrinzolamide/Brimonidine Tart32$6,215
Alphagan PBrimonidine Tartrate12$5,929
Travoprost35$5,261
Timolol Maleate39$1,536
Prednisolone Acetate29$1,237
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat66$925
Brimonidine Tartrate14$683
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$241
Levobunolol Hcl11$22

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →